Neurobehavioral effects of prenatal lamivudine (3TC) exposure in preweaning mice

Neurotoxicology and Teratology

Volumn 21, Issue 4, 1999, Pages 365-373

  Calamandrei, Gemma ^a   Venerosi, Aldina ^a   Branchi, Igor ^b   Valanzano, Angela ^a   Puopolo, Maria ^a   Alleva, Enrico ^b  

^a Ist Superiore di Sanitae   (Italy)

^b Lab Fisiopatol Organo Sistema   (Italy)

Author keywords

HIV; Lamivudine (3TC); Mice; Neurobehavioral development; Zidovudine (AZT)

Indexed keywords

LAMIVUDINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BODY WEIGHT; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG EFFECT; FEMALE; LEARNING; LOCOMOTION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REPRODUCTION; SENSORIMOTOR FUNCTION; ULTRASOUND; VOCALIZATION; WEANING;

ANIMALS; ANTI-HIV AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; FEMALE; FETUS; LAMIVUDINE; MALE; MATERNAL-FETAL EXCHANGE; MICE; PREGNANCY; WEANING;

EID: 0033029880     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(99)00018-5     Document Type: Article

References (43)

1. Adams J. Ultrasonic vocalizations as diagnostic tools in studies of developmental toxicity. An investigation of the effects of hypervitaminosis A Neurobehav. Toxicol. Teratol. 4:1982;299-304.
2. Alleva E., Laviola G., Tirelli E., Bignami G. Short-, medium-, and long-term effects of prenatal oxazepam on neurobehavioral development of mice. Psychopharmacology (Berlin). 87:1985;434-441.
3. AppleWhite-Black L.E., Dow-Edwards D., Minkoff H.L. Neurobehavioral and pregnancy effects of prenatal zidovudine exposure in Sprague-Dawley rats. Preliminary findings Neurotoxicol. Teratol. 20:1998;251-258.
4. Ayers K.M., Torrey C.E., Reynolds D.J. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam. Appl. Toxicol. 38:1997;195-198.
5. Bignami G. Economical test methods for developmental neurobehavioral toxicity. Environ. Health Perspect. 104:1996;285-289.
6. Bignami G., Musi B., Dell'Omo G., Laviola G., Alleva E. Limited effects of ozone exposure during pregnancy on physical and neurobehavioral development of CD-1 mice. Toxicol. Pharmacol. 129:1994;264-271.
7. Busidan, Y.; Ditillo, M. F.; Dow-Edwards, D.: Perinatal AZT (Zidovudine) neurobehavioral effects in the adult rat. Abstract 58, Neurobehavioral Teratology Society Meeting; 1998.
8. CAESAR, Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 349:1413-1421; 1997.
9. Cagiano R., Sales G.D., Renna G., Racagni G., Cuomo V. Ultrasonic vocalization in rat pups. Effects of early postnatal exposure to haloperidol Life Sci. 38:1986;1417-1423.
10. Calamandrei G., Alleva E. Epidermal growth factor has both growth-promoting and growth-inhibiting effects on physical and neurobehavioral development of neonatal mice. Brain Res. 477:1989;1-6.
11. Calamandrei G., Venerosi A., Branchi I., Alleva E. Effects of prenatal zidovudine treatment on learning and memory capacities of preweanling and young adult mice. Neurotoxicology. 20:1999;17-26.
12. Calamandrei G., Venerosi A., Branchi I., Chiarotti F., Verdina A., Bucci F., Alleva E. Effects of prenatal AZT on mouse neurobehavioral development and passive avoidance learning. Neurotoxicol. Teratol. 21:1999;29-40.
13. CDC, Centers of Disease Control: Update: Perinatally acquired HIV/AIDS - United States, 1997. Morb. Mortal. Weekly Rep. 46:1086-1092; 1997.
14. Chiarotti F., Alleva E., Bignami G. Problems of test choice and data analysis in behavioral teratology. The case of prenatal benzodiazepines Neurotoxicol. Teratol. 9:1987;179-186.
15. Cirulli F., Santucci D., Laviola G., Alleva E., Levine S. Behavioral and hormonal responses to stress in the newborn mouse. Effects of maternal deprivation and chlordiazepoxide Dev. Psychobiol. 27:1994;301-316.
16. Elwood R.W., Keeling F. Temporal organization of ultrasonic vocalization in infant mice. Dev. Psychobiol. 15:1982;221-227.
17. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., Kuritzkes D.R., Fallon M.A., Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 333:1995;1662-1669.
18. Fox W.M. Reflex-ontogeny and behavioral development of the mouse. Anim. Behav. 13:1965;234-240.
19. Frenkel L.M., Wagner L.E. II, Demeter L.M., Dewhurst S., Coombs R.W., Murante B.L., Reichman R.C. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin. Infect. Dis. 20:1995;1321-1326.
20. Greene J.A., Ayers K.M., Tucker W.E. Jr., de Miranda P. Nonclinical toxicology studies with zidovudine. Reproductive toxicity studies in rats and rabbits Fundam. Appl. Toxicol. 32:1996;140-147.
21. Ha J.C., Nobisch C., Abkowitz J.L., Conrad S.H., Mottet N.K., Ruppenthal G.C., Robinette R., Sackett G.P., Unadkat J.D. Fetal, infant, and maternal toxicity of zidovudine (azidothymidine) administered throughout pregnancy in Macaca nemestrina. J. Acquir. Immune Defic. Syndrom. 18:1998;27-38.
22. Ha J.C., Nobisch C., Conrad S.H., Ruppenthal G.C., Sackett G.P., Abkowitz J., Unadkat J.D. Fetal toxicity of zidovudine (azidothymidine) in Macaca nemestrina. Preliminary observations J. Acquir. Immune Defic. Syndrom. 7:1994;154-157.
23. Horneff G., Adams O., Wahn V. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children. AIDS. 12:1998;489-494.
24. Hussey E.K., Donn K.H., Daniel M.J., Hall S.T., Harker A.J., Evans G.L. Interspecies scaling and pharmacokinetics parameters of 3TC in humans. J. Clin. Pharmacol. 34:1994;975-977.
25. Johnson, M. A.; Goodwin, C.; Yuen, G. J.; Gray, M. D.; Plumb, R.; Coovadia, H.; Pillay, K.; Moodley, D.; Moodley, J.; Saba, J.: The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring. [Abstract Tu.C.445], XIth International Conference on AIDS, Vancouver, Canada: July 7-12 Vol I: 1996:249-250.
26. Katlama C., Ingrand D., Loveday C., Clumeck N., Mallolas J., Staszewski S., Johnson M., Hill A.M., Pearce G., McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA. 276:1996;118-125.
27. Loy R., Sheldon R.A. Sexually dimorphic development of cholinergic enzymes in the rat septohippocampal system. Dev. Brain Res. 34:1987;156-160.
28. Minkoff H., Augernbraun M. Antiretroviral therapy for pregnant women. Am. J. Obstet. Gynecol. 176:1997;478-489.
29. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., Jones A.B., Rice J.M., Riggs C.W., Logsdon D., Yuspa S.H., Poirier M.C. Transplacental effects of 3′-azido-2′, 3′-dideoxythymidine (AZT). Tumorigenicity in mice and genotoxicity in mice and monkeys J. Natl. Cancer Inst. 89:1997;1602-1608.
30. Perry C.M., Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection Drugs. 53:1997;657-680.
31. Petruzzi S., Fiore M., Dell'Omo G., Bignami G., Alleva E. Medium and long-term behavioral effects in mice of extended gestational exposure to ozone. Neurotoxicol. Teratol. 17:1995;463-470.
32. Petykó Z., Lénád L., Sümegi B., Hajnal A., Csete B., Faludi B., Jandò G. Learning disturbances in offspring of zidovudine (AZT) treated rats. Neurobiology. 5:1997;83-85.
33. Rajagopalan P., Moore L.E., Schinazi R.F., Boudinot F.D. Pharmacokinetics of (-)-β-L 2′,3′-Dideoxy-3′-thiacytine in rats. Pharmaceut. Sci. 2:1996;133-136.
34. Ricceri L., Berger-Sweeney J. Postnatal choline supplementation in preweaning mice. Sexually dimorphic behavioral and neurochemical effects Behav. Neurosci. 112:1998;1-6.
35. 57-70 affect somatic and neurobehavioral development of newborn male mice. Brain Res. Bull. 35:1994;367-371.
36. Schroder M.J., Kaldenbach T., Piroth W. Nuclear and mitochondrial changes of co-cultivated spinal cord, spinal ganglia and muscle fibers following treatment with various doses of zidovudine. Acta Neuropathol. 92:1996;138-149.
37. Sikka C.S., Gogu S.R., Agrawal K.C. Effect of zidovudine (AZT) on reproductive and hematopoietic system in the male rat. Biochem. Pharmacol. 42:1991;1293-1297.
38. Sperling R.S., Stratton P., O'Sullivan M.J., Boyer P., Watts D.H., Lambert J.S., Hammill H., Livingston E.G., Gloeb D.J., Minkoff H., Fox H.E. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N. Engl. J. Med. 326:1992;857-861.
39. Staszewski S., Hill A.M., Bartlett J., Eron J.J., Katlama C., Johnson J., Sawyer W., McDade H. Reduction in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments. A meta-analysis of controlled trials AIDS. 11:1997;477-483.
40. Takahashi L.K., Turner J.G., Kalin N.H. Development of stress-induced responses in preweanlings rats. Dev. Psychobiol. 24:1990;341-360.
41. Taylor L., Gorman J.M., Givon L. The effect of prepartum zidovudine administration on the physical and behavioral development of mice. Pediatric AIDS and HIV Infection: Fetus to Adolescent. 3:1992;308-312.
42. Winslow J.T., Insel T.R. The infant rat separation paradigm. A novel test for novel anxiolytics Trends Pharmacol. Sci. 12:1991;402-404.
43. Yuen G.J., Morris D.M., Mydlow P.K., Haidar S., Hall S.T., Hussey E.K. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1995;1174-1180.